Ajinomoto announced today that it has executed a merger agreement to acquire all of the capital stock of Althea Technologies, Inc. a leading biopharmaceutical CDMO, for approximately USD 175 million (approx. JPY 16 billion). Through this acquisition of Althea Technologies Ajinomoto Co. aims to strengthen its business foundation and expand in the rapidly growing advanced biopharma field. Ajinomoto Co. aspires, including this acquisition, to achieve revenue of JPY 30 billion by 2020.
Key Services:
Transaction Valuation
The transaction values Althea at 3.5 times revenue. In 2012, Althea generated $53million in annual revenues. Althea has about 220 employees
About Athea Technologies
Althea Technologies, located in San Diego, CA, is a contract development and manufacturing organization that specializes in cGMP manufacturing, analytical development, aseptic filling into vials & syringes, and protein delivery technology for recombinant protein and parenteral products. In a single location, Althea has the capacity to meet your early-stage and commercial requirements.Key Services:
- Cell Line Development
- Process Development
- cGMP Protein & DNA Plasmid Production
- Analytical Method Development
- Lyophilization Cycle Development
- Sterile Vial Filling
- Sterile Syringe Filling
- High Concentration Formulations
- Sustained Release Formulations
- Proven Technology
- Proven cGMP Manufacturability at Scale
No comments:
Post a Comment